Polyarteritis nodosa diagnosed in a young male after COVID-19 vaccine: A case report

Abstract

In response to the coronavirus disease 2019 (COVID-19) pandemic, the COVID-19 vaccine was rapidly developed, and the effectiveness of the vaccine has been established. However, various adverse effects have been reported, including development of autoimmune diseases. We report a case of new-onset polyarteritis nodosa (PAN) in a 32-year-old male following COVID-19 vaccination. The patient developed limb pain, fever, pulmonary embolism, and multiple subcutaneous nodules and haematomas. Skin biopsy revealed necrotising inflammation accompanied by fibrinoid necrosis and high inflammatory cell infiltration in the walls of medium to small arteries. The symptoms resolved following corticosteroid treatment. Although it is difficult to prove a relationship between the vaccine and PAN, similar cases have been reported, and further reports and analyses are therefore necessary.

‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA

“…[139] (abstract) Since Rodríguez et al's review, further peer-reviewed case reports keep appearing. A small sample includes autoimmune dermatological and vascular disorders attributed to the COVID-19 vaccines including IgA pemphigus where the "likely cause" was the AstraZeneca COVID-19 vaccine [140]; autoimmune bullous disease with IgG and IgM autoantibodies against epidermal basement membrane zone after mRNA COVID-19 vaccine [141]; polyarteritis nodosa in a 32-year-old male with "limb pain, fever, pulmonary embolism, and multiple subcutaneous nodules and haematomas" following the COVID-19 vaccine [142].…”